Prieto Introduces World’s Fastest-Charging Battery That Charges in 3 Minutes
22.5.2023 16:03:00 EEST | Business Wire | Press release
Prieto Battery, Inc., a world leader in advanced lithium-ion battery technology, unveiled the most recent prototype of its patented 3D interdigitated battery that delivers groundbreaking performance:
- 3-minute hyper-fast charge
- Operates and charges in extremely low (-30 degrees C) and high (+100 degrees C) temperatures
- Nonflammable
All three attributes of Prieto’s lithium-ion battery were tested and validated by a third-party accredited battery testing lab.
Hyper-Fast Charge
“Prieto’s battery will charge faster than you can fill your car’s gas tank,” said Mike Rosenberg, Prieto CEO. “When you charge your car faster than gassing up, range is no longer a hindrance and everyone becomes a potential EV buyer.”
Due to its 3D architecture, Prieto’s battery fully charges in three minutes and achieves a 50% charge in 90 seconds, regardless of size.
“A three-minute charge fundamentally changes how companies can design their products and how consumers use them,” added Rosenberg.
All-Weather Extreme Temperature Operation
The Prieto 3D battery delivers the industry’s widest temperature operation. Not only does it operate at -30 degrees C (-22 degrees F), but it also charges at that temperature. The battery also operates and is safe at temperatures as high as +100 degrees C (212 degrees F).
“Prieto’s battery is the only battery that we are aware of that will not only operate, but will also charge at -30 degrees Celsius,” explained Rosenberg. “As we learned this past winter when extreme cold weather hit North America, many people were left stranded with dead EVs. Our battery would have allowed these EVs to continue to operate and charge, instilling confidence in drivers to rely on their EVs even in extreme temperatures.”
Nonflammable
Prieto’s 3D architecture and design ensure that the battery is not flammable or combustible. A third-party lab conducted the gold standard “nail penetration test” on Prieto’s battery that resulted in no fire or explosion, and the battery continued to operate.
“Prieto’s battery operates safely and will not catch fire like traditional lithium-ion batteries,” Rosenberg said. “The 3D architecture and the materials we use ensure that our batteries will not experience thermal runaways or fires, which gives consumers peace of mind.”
3D Interdigitated Technology
“Our founder, Dr. Amy Prieto, reimagined the entire architecture of a conventional battery and developed the first 3D interdigitated battery,” said Rosenberg. “We’re introducing a better architecture and a better process, which results in a better battery and a superior consumer experience. This is truly the next evolution that will redefine the way we power our lives.”
Prieto’s 3D architecture is completely different from all other batteries. Today’s batteries use a decades-old 2D architecture that must always compromise between energy storage and fast charging. In 2D batteries, energy can only flow in one direction across a two-dimensional plane. To charge, lithium ions must flow from one surface to the other, resulting in serious limitations. Thicker 2D batteries store more energy, but the long ion pathways result in slow charging. Thinner 2D batteries can charge faster but cannot store much energy.
“We’ve dramatically shortened the diffusion length in any direction, which takes charging to hyper-speed and delivers more power and energy storage than 2D batteries,” said Dr. Prieto, founder and chief technology officer of Prieto. “The core of our battery looks like a thin copper sponge, and the ions only have to travel from one strand to the next, a fraction of the distance in traditional 2D batteries.”
Prieto’s battery is designed to deliver five times the power density (20C discharge rate) and up to three times the energy density of conventional 2D batteries. It is customizable to any size or application, making it ideal for anything from electric vehicles to power tools, medical devices to mobile phones and small home appliances.
Simple, Cost-Effective Manufacturing
Prieto’s new battery boasts a unique manufacturing advantage because it is made from low-cost, sustainable materials with a simple and scalable process. Prieto uses a proven water-based electroplating process at room temperature and its process requires no dry rooms, clean rooms, or other expensive equipment.
“From day one I prioritized manufacturing ahead of the battery design, and I knew to reimagine the battery we would first have to simplify production to scale up quickly, efficiently, and affordably,” said Dr. Prieto.
Prieto’s current laboratory manufacturing yield rates are more than 90%.
“We now turn our focus to commercialization as we finalize plans to build our pilot manufacturing facility,” said Rosenberg. “Our high yield rates, combined with our simple and familiar manufacturing process used in many other industries, will ultimately result in much lower costs than traditional lithium-ion batteries and gives us a great degree of confidence.”
Prieto is currently in discussions for manufacturing and applications with potential partners.
About Prieto
Prieto developed a proprietary 3D interdigitated lithium-ion battery that delivers transformational performance, such as hyper-fast charging, wide temperature operations and is safe, at a competitive cost. Its battery is customizable to all shapes and sizes for use in electric vehicles, consumer electronics and commercial equipment. Prieto also patented a unique electroplating manufacturing process that uses non-toxic materials without the need for highly specialized facilities. The company was founded in 2009. Prieto’s lab and headquarters are in Fort Collins, Colorado. Visit prietobattery.com.
About Dr. Amy Prieto
Dr. Prieto is the founder and chief technology officer at Prieto. She earned her doctorate in Chemistry from the University of California, Berkeley, and completed her postdoctoral work at Harvard University. She received the Presidential Early Career Award for Scientists and Engineers for this battery technology and is recognized by the Smithsonian Institution, where her innovation is on display in its museum in Washington, D.C.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005396/en/
Contact information
Lisa Metzger
lisametzger@avocetcommunications.com
John Hall
john@avocetcommunications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
